Physician profile
Anne D Hogsett
NPI 1699093583
$974.37
in general payments reported to CMS, 2019-2025
14 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.97 · 2020: $27.77 · 2021: $57.72 · 2022: $218 · 2023: $315 · 2024: $201 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $172.81 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $121.00 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $95.02 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $57.08 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.77 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $25.26 | 2019-2023 | Proquad, Pneumovax 23, Vaxneuvance |
| Biogen, INC. | $22.16 | 2021 | |
| Amgen INC. | $16.50 | 2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.34 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $13.07 | 2024 | Bexsero, Arexvy, Shingrix |
| Pfizer INC. | $12.39 | 2020 | |
| Daiichi Sankyo INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Hogsett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.